RxDoctor Payments Data

Romana Usman, MD

Internal Medicine · San Francisco, CANPI 1538200852

Payments from drug & device makers

$1,867in general payments, 2019–2025

Across 102 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$315
  • Viiv Healthcare Company$227
  • Gilead$214
  • GSK$124
  • Sanofi-aventis U.S. LLC$120
  • AbbVie$106
  • plus $762 from 18 others

What the payments were for

  • Food & beverage$1,867100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,867 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$39,503
Medicare patients
72
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OdefseyEmtricitab/Rilpiviri/Tenof Ala17$63,388
PrezcobixDarunavir/Cobicistat16$38,693
TivicayDolutegravir Sodium14$35,066
EliquisApixaban27$25,641
JanuviaSitagliptin Phosphate22$23,828
JardianceEmpagliflozin19$18,655
MyrbetriqMirabegron19$11,534
Breo ElliptaFluticasone/Vilanterol30$10,821
XareltoRivaroxaban14$7,864
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl18$5,850
Trazodone Hcl44$2,333
Levothyroxine Sodium87$1,312
Estradiol20$1,233
Atorvastatin Calcium171$1,197
Metoprolol Succinate97$1,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonPrezcobix, Xarelto$16$46,55730 claims
Viiv Healthcare CompanyTivicay$227$35,06614 claims
PfizerEliquis$30$25,64127 claims
MerckJanuvia$96$23,82822 claims
Boehringer IngelheimJardiance$90$18,65519 claims
Astellas Pharma US IncMyrbetriq$24$11,53419 claims
GSKBreo Ellipta$124$10,82130 claims
AbbVieSynthroid$106$47013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →